Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$42.76 USD
+0.93 (2.22%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $42.71 -0.05 (-0.12%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
GPCR 42.76 +0.93(2.22%)
Will GPCR be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GPCR
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics (GPCR) Stock Up 9% This Week: Here's Why
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
IPO Round Up of First Half of 2023
Other News for GPCR
The 3 Smartest Biotech Stocks to Buy With $5K Right Now
Jefferies Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Maintained Buy Rating: Overreaction to Sell-off Undervalues Structure Therapeutics’ Market Potential
Lilly, Novo Nordisk to dominate weight loss therapy market: SA Investing Summit
Structure Therapeutics: Yet Another Potential GLP-1 Entrant